<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721055</url>
  </required_header>
  <id_info>
    <org_study_id>XHEC-C-2017-029-2</org_study_id>
    <nct_id>NCT03721055</nct_id>
  </id_info>
  <brief_title>Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor</brief_title>
  <official_title>18F-(2S,4R)4-Glutamine PET/CT in Imaging Patients With Malignant Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies positron emission tomography (PET) imaging utilizing
      18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with malignant
      tumor. [18F]Fluoroglutamine PET may provide additional information that help diagnose and
      stage cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosing and Staging ability of 4-[18F]Fluoroglutamine PET/CT in malignant cancer</measure>
    <time_frame>up to three years</time_frame>
    <description>Sensitivity, specificity, diagnostic accuracy of 4-[18F]Fluoroglutamine and 18F-FDG PET/CT will be compared using paired t-test or Krusal-Wallis test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>up to 30 days after the F-Gln imaging</time_frame>
    <description>The evaluation of the Incidence of Treatment-Emergent Adverse Events starts from the day of F-Gln examination until 30 days later; Treatment-Emergent Adverse Events are evaluated according to version 4.03 CTC-AE criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASCT2 expression levels in tissue samples</measure>
    <time_frame>up to three years</time_frame>
    <description>Wilcoxon rank-sum or Kruskal-Wallis tests will be applied for the group comparisons of IHC staining(ASCT2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between 18F-(2S,4R)4- glutamine PET/CT imaging and prognosis in malignant tumors</measure>
    <time_frame>up to three years</time_frame>
    <description>Evaluating the prognostic value of metabolic parameters and clinical indexes by using log-rank tests on univariate analysis and COX proportional hazards regression tests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Metastatic Brain Cancer</condition>
  <arm_group>
    <arm_group_label>4-[18F]Fluoroglutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-(2S,4R)4-fluoroglutamine</intervention_name>
    <description>Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT</description>
    <arm_group_label>4-[18F]Fluoroglutamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-79;

          -  The patient must be able to give informed consent;

          -  Patients can finish PET/CT scan without tranquilizers;

          -  Patients with pathology-proven cancer or a tumor highly suspected to be malignant ;

          -  Lesions can be measured and assessed at the RECIST 1.1 standard;

          -  No chemotherapy, radiotherapy or immune/biologic therapy,or biopsy were allowed
             between the 18F-FDG and the 4-[18F]Fluoroglutamine PET/CT.

        Exclusion Criteria:

          -  Pregnant or lactating patients;

          -  Inability or refusal to have at least one peripheral intravenous line for intravenous
             access;

          -  From assays obtained &lt;2 weeks prior to study enrollment（ULN：the upper limit of normal
             value ）:Bilirubin&gt;1.5*ULN,AST/ALT &gt;2.5 * ULN, Albumin&lt; 3 g/dl, GGT &gt; 2.5 x ULN if ALP&gt;
             2.5 x ULN, Creatinine&gt;1.5*ULN or creatinine clearance &lt;60ml/min；

          -  Patients with a history of allergic reaction to this drugs or its analogues；

          -  patients with poor compliance;

          -  Acute major illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui Wang, MD</last_name>
    <phone>86-02125078590</phone>
    <email>wanghauishanghai@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Wang, MD</last_name>
      <phone>86-02125078590</phone>
      <email>wanghauishanghai@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

